GSA Capital Partners LLP acquired a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 151,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,218,000. GSA Capital Partners LLP owned about 0.34% of CymaBay Therapeutics at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of CBAY. Renaissance Technologies LLC grew its stake in CymaBay Therapeutics by 97.6% in the 1st quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after acquiring an additional 114,549 shares during the period. Bank of New York Mellon Corp grew its stake in shares of CymaBay Therapeutics by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 140 shares during the period. Marshall Wace North America L.P. purchased a new stake in shares of CymaBay Therapeutics during the 2nd quarter valued at $242,000. Vanguard Group Inc. grew its stake in shares of CymaBay Therapeutics by 20.7% during the 2nd quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock valued at $5,712,000 after buying an additional 170,126 shares during the period. Finally, Ardsley Advisory Partners boosted its position in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares during the period. Hedge funds and other institutional investors own 69.12% of the company’s stock.
In other CymaBay Therapeutics news, Director Carl Goldfischer sold 18,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $8.66, for a total value of $155,880.00. Following the completion of the sale, the director now owns 9,000 shares in the company, valued at approximately $77,940. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kurt Von Emster sold 4,300 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $10.21, for a total transaction of $43,903.00. Following the completion of the sale, the director now owns 90,000 shares of the company’s stock, valued at approximately $918,900. The disclosure for this sale can be found here. Over the last three months, insiders have sold 304,749 shares of company stock valued at $2,841,832. Company insiders own 15.10% of the company’s stock.
A number of analysts recently weighed in on CBAY shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $12.00 price objective on shares of CymaBay Therapeutics in a report on Friday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price objective on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Oppenheimer set a $15.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Leerink Swann restated a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $14.50.
CymaBay Therapeutics Inc (CBAY) traded up $0.06 during midday trading on Friday, reaching $9.97. 314,250 shares of the company’s stock traded hands, compared to its average volume of 557,775. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04. The company has a market cap of $437.33, a PE ratio of -9.87 and a beta of 1.82. CymaBay Therapeutics Inc has a 1 year low of $1.46 and a 1 year high of $10.25.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same quarter last year, the company posted ($0.25) EPS. equities research analysts anticipate that CymaBay Therapeutics Inc will post -0.82 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “GSA Capital Partners LLP Buys Shares of 151,100 CymaBay Therapeutics Inc (NASDAQ:CBAY)” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/13/151100-shares-in-cymabay-therapeutics-inc-cbay-acquired-by-gsa-capital-partners-llp-updated-updated.html.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.